Animal models for steroid-induced osteonecrosis

Takuaki Yamamoto, Keita Miyanishi, goro motomura, Kenjiro Nishida, Yukihide Iwamoto, Katsuo Sueishi

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia. Detailed clinical and laboratory evaluations of coagulation system are recommended in those patients who develop manifestations of an abnormal lipid metabolism shortly after high-dose corticosteroid therapy. Moreover, we investigated the effects of the combination treatment with an anticoagulant (warfarin) plus a lipid-lowering agent (probucol) on prevention of steroid-induced osteonecrosis (ON) in this animal model. The incidence of ON in warfarin plus probucol (5%) was significantly lower than that observed in the control group (70%) (p <0.0001). Our results experimentally showed that the combined use of an anticoagulant and a lipid-lowering agent helps prevent steroid-induced ON in rabbits.

Original languageEnglish
Pages (from-to)879-886
Number of pages8
JournalClinical calcium
Volume17
Issue number6
Publication statusPublished - Jan 1 2007

Fingerprint

Osteonecrosis
Animal Models
Steroids
Probucol
Warfarin
Anticoagulants
Lipids
Methylprednisolone
Hyperlipidemias
Lipid Metabolism
Thrombocytopenia
Adrenal Cortex Hormones
Rabbits
Control Groups
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Yamamoto, T., Miyanishi, K., motomura, G., Nishida, K., Iwamoto, Y., & Sueishi, K. (2007). Animal models for steroid-induced osteonecrosis. Clinical calcium, 17(6), 879-886.

Animal models for steroid-induced osteonecrosis. / Yamamoto, Takuaki; Miyanishi, Keita; motomura, goro; Nishida, Kenjiro; Iwamoto, Yukihide; Sueishi, Katsuo.

In: Clinical calcium, Vol. 17, No. 6, 01.01.2007, p. 879-886.

Research output: Contribution to journalReview article

Yamamoto, T, Miyanishi, K, motomura, G, Nishida, K, Iwamoto, Y & Sueishi, K 2007, 'Animal models for steroid-induced osteonecrosis', Clinical calcium, vol. 17, no. 6, pp. 879-886.
Yamamoto T, Miyanishi K, motomura G, Nishida K, Iwamoto Y, Sueishi K. Animal models for steroid-induced osteonecrosis. Clinical calcium. 2007 Jan 1;17(6):879-886.
Yamamoto, Takuaki ; Miyanishi, Keita ; motomura, goro ; Nishida, Kenjiro ; Iwamoto, Yukihide ; Sueishi, Katsuo. / Animal models for steroid-induced osteonecrosis. In: Clinical calcium. 2007 ; Vol. 17, No. 6. pp. 879-886.
@article{f749ca3bbea94337a4e33ffb008e4143,
title = "Animal models for steroid-induced osteonecrosis",
abstract = "We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia. Detailed clinical and laboratory evaluations of coagulation system are recommended in those patients who develop manifestations of an abnormal lipid metabolism shortly after high-dose corticosteroid therapy. Moreover, we investigated the effects of the combination treatment with an anticoagulant (warfarin) plus a lipid-lowering agent (probucol) on prevention of steroid-induced osteonecrosis (ON) in this animal model. The incidence of ON in warfarin plus probucol (5{\%}) was significantly lower than that observed in the control group (70{\%}) (p <0.0001). Our results experimentally showed that the combined use of an anticoagulant and a lipid-lowering agent helps prevent steroid-induced ON in rabbits.",
author = "Takuaki Yamamoto and Keita Miyanishi and goro motomura and Kenjiro Nishida and Yukihide Iwamoto and Katsuo Sueishi",
year = "2007",
month = "1",
day = "1",
language = "English",
volume = "17",
pages = "879--886",
journal = "Clinical calcium",
issn = "0917-5857",
publisher = "Iyaku (Medicine & Drug) Journal Co",
number = "6",

}

TY - JOUR

T1 - Animal models for steroid-induced osteonecrosis

AU - Yamamoto, Takuaki

AU - Miyanishi, Keita

AU - motomura, goro

AU - Nishida, Kenjiro

AU - Iwamoto, Yukihide

AU - Sueishi, Katsuo

PY - 2007/1/1

Y1 - 2007/1/1

N2 - We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia. Detailed clinical and laboratory evaluations of coagulation system are recommended in those patients who develop manifestations of an abnormal lipid metabolism shortly after high-dose corticosteroid therapy. Moreover, we investigated the effects of the combination treatment with an anticoagulant (warfarin) plus a lipid-lowering agent (probucol) on prevention of steroid-induced osteonecrosis (ON) in this animal model. The incidence of ON in warfarin plus probucol (5%) was significantly lower than that observed in the control group (70%) (p <0.0001). Our results experimentally showed that the combined use of an anticoagulant and a lipid-lowering agent helps prevent steroid-induced ON in rabbits.

AB - We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia. Detailed clinical and laboratory evaluations of coagulation system are recommended in those patients who develop manifestations of an abnormal lipid metabolism shortly after high-dose corticosteroid therapy. Moreover, we investigated the effects of the combination treatment with an anticoagulant (warfarin) plus a lipid-lowering agent (probucol) on prevention of steroid-induced osteonecrosis (ON) in this animal model. The incidence of ON in warfarin plus probucol (5%) was significantly lower than that observed in the control group (70%) (p <0.0001). Our results experimentally showed that the combined use of an anticoagulant and a lipid-lowering agent helps prevent steroid-induced ON in rabbits.

UR - http://www.scopus.com/inward/record.url?scp=34547134265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547134265&partnerID=8YFLogxK

M3 - Review article

C2 - 17548927

AN - SCOPUS:34547134265

VL - 17

SP - 879

EP - 886

JO - Clinical calcium

JF - Clinical calcium

SN - 0917-5857

IS - 6

ER -